medigraphic.com

2014, Number 3

<< Back Next >>

Rev Cuba Endoc 2014; 25 (3)

Subclinical hypercortisolism

Cabrera GM, Turcios TSE

Language: Spanish
References: 23
Page: 237-242
PDF size: 52.75 Kb.


ABSTRACT

Subclinical hypercortisolism is an alteration of the hypothalamus-hypophysisadrenal axis in absence of classical symptoms and signs of excessive cortisol. It is an endocrine disease that affects up to 20 % of patients diagnosed with an adrenal tumor. The research studies indicate the hypothesis that this entity could be associated to chronic complications such as blood hypertension, diabetes mellitus, overweight/obesity and osteoporosis. The diagnosis and treatment of subclinical hypercortisolism has turned into a topic of growing interest and discussion nowadays, but the consensus is still pending. It is then necessary to perform prospective and randomized studies in order to confirm the suggested hypothesis, to determine the best way of making a diagnosis and to select the patients who are going to really benefit from a surgical treatment.


REFERENCES

  1. Terzolo M, Pia A, Reimondo G. Subclinical Cushing’s syndrome: definition and management. Clin Endocrinol. 2012;76:12-8.

  2. Stewart PM. Is subclinical Cushing’s Syndrome an Entity or a Statistical Fallout from Diagnostic Testing? Consensus Surrounding the Diagnosis Is Required before Optimal Treatment Can Be Defined. J Clin Endocrinol Metab. 2010;95(6):2618-20.

  3. Young Jr WF. Management approaches to adrenal incidentalomas: a view from Rochester, Minnesota. Endocrinol Metab Clin North Am. 2000;9:159-85.

  4. Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A, Boscaro M. Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab. 1999;84:520-6.

  5. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003;149:273-85.

  6. Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Grumbach, et al. Management of the clinically inapparent adrenal mass (‘incidentaloma’). Ann Int Med. 2003;138:424-9.

  7. Terzolo M, Bovios S, Pia A, Osella G, Borretta G, Angelia A, et al. Subclinical Cushing’s syndrome. Arq Bras Endocrinol Metab. 2007;51(8):1272-9.

  8. Terzolo M, Bovio S, Reimondo G, Pia A, Osella G, Borretta G, et al. Subclinical Cushing’s syndrome in adrenal incidentalomas. Endocrinol Metabol Clin North Am. 2005;34:423-39.

  9. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-40.

  10. Chiodini I. Diagnosis and Treatment of Subclinical Hypercortisolism. J Clin Endocrinol Metab. 2011;96:1223-36.

  11. Terzolo M, Bovio S, Pia A, Conton PA, Reimondo G, Dall’Asta C, et al. Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur J Endocrino. 2005;153:307-15.

  12. Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J Endocrinol Invest. 2006;29:471-82.

  13. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cavagnini F. Specificity of first-line tests for the diagnosis of Cushing’s syndrome: assessment in a large series. J Clin Endocrinol Metab. 2007;92:4123-9.

  14. Terzolo M, Stigliano A, Chiodini I. AME Position Statement on adrenal incidentaloma. Eur J Endoc. 2011;164:852-70.

  15. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:5593-602.

  16. Tsagarakis S, Roboti C, Kokkoris P, Vasiliou V, Alevizaki C, Thalassinos N. Elevated postdexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas. Clin Endocrinol (Oxford). 1998;49:165-71.

  17. Tanabe A, Naruse M, Nishikawa T, Yoshimoto T, Shimizu T, Seki T, et al. Autonomy of cortisol secretion in clinically silent adrenal incidentaloma. Hormone and Metabolic Research. 2001;33:444-50.

  18. Libè R, Dall'Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P, Ambrosi B. Longterm followup study of patients with adrenal incidentalomas. Eur J Endoc. 2002;147:489-94.

  19. Chiodini I, Morelli V, Salcuni AS, Eller-Vainicher C, Torlontano M, Coletti F, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab. 2010;95:2736-45.

  20. NIH State-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”). NIH Consensus and State-of-the-Science Statements. 2002;19:1-23.

  21. Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract. 2009;15(Suppl 1):1-20.

  22. Reimondo G, Pia A, Bovio S, Allasino B, Daffara F, Paccotti P. et al. Laboratory differentiation of Cushing’s syndrome. Clin Chim Acta. 2008;388:5-14.

  23. Terzolo M, Bovio S, Pia A, Conton P A, Reimondo G, Dall’Asta C. et al. Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur J Endocrinol. 2005;153:307-15.




2020     |     www.medigraphic.com